method for treating, ameliorating, or preventing a disorder, fusion protein, vector, recombinant host cell, method for producing a fusion protein, pharmaceutical composition, and methods for transplanting / grafting an organ, tissue, cell or cell group into a mammalian individual, and to treat, prevent or ameliorate transplant / graft rejection in a mammalian transplant / graft recipient

摘要

METHOD FOR TREATING, IMPROVING, OR PREVENTING A DISORDER, FUSION PROTEIN, VECTOR, RECOMBINANT HOST CELL, METHOD FOR PRODUCTING A FUSION PROTEIN, PHARMACEUTICAL COMPOSITION, AND A CELL, A MEXULAR A MAMMALIAN INDIVIDUAL, AND TO TREAT, PREVENT, OR IMPROVE TRANSPLANT / Graft Rejection IN A MAMMALLY TRANSPLANT / Graft RECEIVER Methods and compositions for inhibiting interleukin-21 (IL-21) / IL-21 (MU-1) receptor activity using IL-21 antagonists or IL-21 receptor ("IL-21R" or "MU-1") are described. IL-21 / IL-21R antagonists may be used to induce immune suppression in vivo, eg to treat, ameliorate or prevent autoimmune or inflammatory disorders, including, eg, inflammatory bowel disease (IBD), rheumatoid arthritis (RA). ), transplant / graft rejection, psoriasis, asthma, fibrosis, and systemic lupus erythematosus (SLE).